Evocalcet clinical trials
Also written KHK7580.
How each study uses evocalcet is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2017 | 1 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses evocalcet is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in AsiaCompletedPhase 3Kyowa Kirin Co., Ltd.NCT03822507Written as KHK7580
- Pharmacokinetic Study of KHK7580 in Healthy Adult VolunteersCompletedPhase 1Kyowa Kirin Co., Ltd.NCT04206657Written as 1mg KHK7580
- Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary HyperparathyroidismCompletedPhase 3Kyowa Kirin Co., Ltd.NCT03280264Written as KHK7580
- Phase 2 Study of KHK7580CompletedPhase 2Kyowa Kirin Co., Ltd.NCT02216656Written as KHK7580 low dose
- Phase 3 Study of KHK7580CompletedPhase 3Kyowa Kirin Co., Ltd.NCT02549404Written as KHK7580
- Phase 3 Study of KHK7580CompletedPhase 3Kyowa Kirin Co., Ltd.NCT02549417Written as KHK7580
- Phase 3 Study of KHK7580CompletedPhase 2/3Kyowa Kirin Co., Ltd.NCT02549391Written as KHK7580
- Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving HemodialysisCompletedPhase 1/2Kyowa Kirin Co., Ltd.NCT01935856Written as KHK7580
- Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal DialysisCompletedPhase 1Kyowa Kirin Co., Ltd.NCT02143271Written as KHK7580
Codes
What other systems call evocalcet · ClinicalTrials.gg INT001112
- MeSH (NLM) C000631688evocalcetOne source NLM
- UNII (FDA) E58MLH082PEVOCALCETConfirmed FDA, NLM, Wikidata
- Wikidata Q27077250evocalcetConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C153105EvocalcetOne source FDA
- DrugBank DB12388One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000631688 | evocalcet | One source NLM |
| UNII (FDA) | E58MLH082P | EVOCALCET | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27077250 | evocalcet | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C153105 | Evocalcet | One source FDA |
| DrugBank | DB12388 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.